ecancer

ecancer.org

ecancer is a UK charity which provides accessible, high-quality educational content, free to the global oncology community. Our mission is to raise the standards of care for cancer patients across the world through education.

 

ecancer
R

Targeting BRAF V600E in mCRC: Where Are We Today?

By ecancer FEATURING Rodrigo Motta Guerrero
By ecancer FEATURING Rodrigo Motta Guerrero
76 views
September 1, 2023
0 Comments
Login to view comments. Click here to Login

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay

Featured Video

17:33
AstraZeneca Oncology

First-line Maintenance Therapy for BRCAm Advanced Ovarian Cancer Fol…

Feat. S. Lewin
GI Cancers
05:19
ecancer

Targeting BRAF V600E in mCRC: Where Are We Today?

Feat. R. Motta Guerrero
08:33
ecancer

Effectiveness and Tolerability of Cetuximab With XELOX or XELIRI in …

Feat. J. Zekri
07:28
ecancer

Durable Effect of Imatinib & Metronomic Chemo With Capecitabine …

Feat. S. Al-Sukhun
06:31
ecancer

CheckMate 649 Trial Biomarker Analyses of Nivo + Ipi vs. Chemo for P…

Feat. Y. Y. Janjigian
04:43
ecancer

Initial Results From a Phase 1 GLIMMER-01 Trial: Efficacy of Dose Es…

Feat. J. Luke
07:45
ecancer

Latest Treatments in Esophageal Cancer

Feat. C. Bizekis
04:11
ecancer

CRYSTAL Trial: Left vs. Right Sided GI Tumor Response

Feat. E. Van Cutsem
10:08
ecancer

ESMO GI 2022 on CRC: Impact of BRAF-V600E Mutation on Tumor Microenv…

Feat. M. Salem
04:46
ecancer

ESMO GI 2022 Update on MOUNTAINEER Trial: Tucatinib in Combination W…

Feat. J. Strickler
04:53
ecancer

Optimum Treatment Strategy Algorithm for mCRC

Feat. H. Lenz
05:41
ecancer

An Overview of Treatment Advances in Gastric Cancer

Feat. D. Ilson
16:00
ecancer

Tumor Agnostic Treatments in GI Cancers: Liquid Bipsy, Biomarkers

Feat. N. Normanno, K. Schmitz
07:48
ecancer

Tremelimumab and Durvalumab as 1L in Unresectable HCC: Phase 3 HIMAL…

Feat. G. Abou-Alfa
06:19
ecancer

Early Treatment Discontinuation and Early Oxaliplatin Discontinuatio…

Feat. C. Gallois
06:04
ecancer

ASCO GI 2022: OS With Durvalumab + Chemo in Advanced Biliary Tract C…

Feat. D. Oh
04:06
ecancer

ESMO 2021 Updates on Adagrasib +/- Cetuximab for CRC Patients Harbor…

Feat. J. Weiss
09:04
ecancer

2L Yttrium-90 Radioembolization With Chemo for CRC Liver Metastases

Feat. M. Mulcahy
05:16
ecancer

ESMO 2021 Data on Anti-TIGIT Antibody Tiragolumab + Atezolizumab in …

Feat. Z. Wainberg
05:39
ecancer

ESMO 2021 Update on BRAFV600E mCRC: cfDNA BRAF Mutant Allele Fractio…

Feat. E. Elez
07:19
ecancer

ESMO 2021 Data on 1L Bevacizumab in CRC With BRAF Mutation: BEACON C…

Feat. D. Aderka
05:54
ecancer

2020 ESMO Updates on GI Cancers: 1L Nivo + Chemo in Advanced GC/GEJC…

Feat. B. Gyawali
08:16
ecancer

2020 ESMO Update on CheckMate 577: Does Nivolumab Demonstrate DFS Im…

Feat. R. Kelly
06:26
ecancer

2020 ESMO Update on CheckMate 459: What Are the OS Outcomes With 1L …

Feat. B. Sangro
08:38
ecancer

2020 ESMO Update on 1L Non-HER2+ Advanced GC/GEJ/EC: Will Nivolumab …

Feat. M. Moehler